Characteristic | Gastric carcinoid present | Gastric carcinoid absent | ||
---|---|---|---|---|
MEN-1 present (n = 14) | MEN-1 absent (n = 2) | MEN-1 present (n = 25) | MEN-1 absent (n = 121) | |
Age (y) | ||||
Mean ± SEM | 50 ± 3 | 61 ± 8 | 48 ± 2 | 56 ± 1 |
Range | 34–69 | 52–70 | 26–75 | 19–80 |
No. of men | 8 (67) | 2 (100) | 11 (41) | 71 (58) |
Disease duration (y)* | ||||
Mean ± SEM | 17 ± 2 | 16 ± 3 | 12 ± 2 | 15 ± 1 |
Range | 8–31 | 13–19 | 2–29 | 1–42 |
Time from disease onset to gastric carcinoid (y)† | ||||
Mean ± SEM | 11 ± 1 | 10 ± 1 | NA | NA |
Range | 6–17 | 9–12 | ||
Endoscopic findings in patients with a carcinoid‡ | ||||
Gastric nodule present | 9 (64) | 1 (50) | NA | NA |
Gastric nodule absent | 3 (21) | 1 (50) | NA | NA |
Positive gastric SRS localization | 12 (86) | 0 (0) | 4 (16) | 3 (2) |
Diffuse pattern | 8 (57) | 0 (0) | 3 (12) | 3 (2) |
Diffuse and focal pattern | 4 (29) | 0 (0) | 0 (0) | 0 (0) |
Negative gastric SRS localization | 2 (14) | 2 (100) | 21 (84) | 118 (98) |
Fasting gastrin level (pg/mL) | ||||
Mean ± SEM | 23,900 ± 11,000 | 19,460 ± 18,500 | 1,000 ± 430 | 5,200 ± 3,200 |
Range | 190–123,000 | 920–38,000 | 57–10,000 | 21–380,000 |
Associated endocrine tumors present (besides gastrinomas) | ||||
Parathyroid only | 6 (50) | NA | 13 (50) | NA |
Pituitary only | 0 (0) | NA | 1 (4) | NA |
Parathyroid and pituitary | 3 (25) | NA | 9 (35) | NA |
Parathyroid and thymic carcinoid | 2 (17) | NA | 1 (4) | NA |
Parathyroid, pituitary, and bronchial carcinoid | 1 (8) | NA | 3 (12) | NA |
↵* Disease duration was time from onset of disease to time of this study.
↵† Time from ZES onset to diagnosis of gastric carcinoid was calculated from time of disease onset until diagnosis of gastric carcinoid was first made histologically.
↵‡ Gastric nodule present or absent refers to endoscopic findings in stomach at time diagnosis of gastric carcinoid tumor was made histologically.
NA = not applicable.
Values in parentheses are percentages.